Ozempic and Pregnancy: What You Need to Know Before Starting or Stopping

There is a question that thousands of women on GLP-1 medications are quietly carrying: what happens if I want to get pregnant? The answer involves more than just stopping a medication. It involves timing, weight management, the unexpected fertility effects these drugs can have, and a plan for the metabolic transition that protects both the pregnancy and the progress made during treatment.

Most people are not getting clear answers to this question from their prescribers — partly because the evidence is still emerging and partly because GLP-1 medications were not originally developed with reproductive planning in mind. This article brings together what is currently known.

What the FDA Guidance Actually Says

The prescribing information for semaglutide — which covers both Ozempic and Wegovy — states explicitly that women who wish to become pregnant should stop the medication at least 2 months before attempting conception. The American College of Obstetricians and Gynecologists (ACOG) echoes this with the same 8-week minimum recommendation.

The reason for the 2-month window is pharmacokinetic. Semaglutide has a half-life of approximately 7 days. It takes approximately 5 half-lives — roughly 5 weeks — for the drug to clear the body to negligible levels. The 2-month recommendation builds an additional safety buffer on top of that clearance period, ensuring the medication has fully left the system before conception occurs.

For tirzepatide (Mounjaro, Zepbound), Eli Lilly’s prescribing information carries equivalent guidance. The same 2-month minimum applies. The half-life of tirzepatide is approximately 5 days, making clearance slightly faster than semaglutide — but the conservative 2-month recommendation covers both adequately.

What the Evidence Shows About Fetal Safety

The honest answer is that human data is limited — not because the medications are known to be dangerous, but because adequately powered clinical trials in pregnant women are not ethically possible to run. What exists is a combination of animal study data and emerging observational human data.

Animal studies

Animal studies with semaglutide in pregnant cynomolgus monkeys and rats showed potential fetal harm including cardiovascular malformations, skeletal variations, reduced fetal growth, and more frequent early pregnancy losses at doses relevant to human therapeutic exposures. These findings are the primary basis for the pregnancy warning on all GLP-1 medications.

However, an important caveat applies: many of these effects in animal studies occurred alongside significant maternal weight loss, making it difficult to determine whether the medication itself or the caloric restriction it caused was responsible for the fetal effects. Weight loss during pregnancy is independently associated with poor fetal outcomes regardless of the cause.

Emerging human data

Human observational data — studies examining pregnancies where GLP-1 exposure occurred, often unexpectedly in the first trimester — has been more reassuring than animal data might suggest.

A 2025 study published in Basic & Clinical Pharmacology and Toxicology examined 32 pregnancies with semaglutide exposure alongside insulin. Researchers found comparable rates of malformations, preterm birth, and neonatal complications compared to pregnancies exposed only to insulin. A larger multicenter observational study from European Teratology Information Services analysed 168 pregnancies with first-trimester GLP-1 exposure and did not find elevated rates of major birth defects compared to population baseline rates of 3–5%.

These findings are early, the sample sizes are small, and they do not provide sufficient evidence to recommend GLP-1 use during pregnancy. The precautionary guidance remains: stop before conception. But they do provide some reassurance for women who discovered a pregnancy while already taking these medications.

Stopping Guidance By Medication

What Are Ozempic Babies?

The term Ozempic babies emerged in 2023 and 2024 to describe pregnancies occurring in women who became pregnant while taking GLP-1 medications — often unexpectedly. It is not an official medical term, but it captures a real phenomenon with a specific biological explanation.

GLP-1 medications improve insulin sensitivity and produce weight loss. In women with insulin resistance or PCOS — a very large subset of the women taking these medications — improved insulin sensitivity can restore more regular ovulation. Women who were previously not ovulating consistently may begin ovulating regularly on GLP-1 therapy, making conception possible when it was not before.

This effect is compounded by an important practical issue: women who have been using hormonal contraception may have assumed their contraception was doing the heavy lifting, not realising that they were also previously anovulatory. When GLP-1 therapy restores ovulation, the contraception remains effective — but women not using contraception who assumed they were infertile due to PCOS may discover they were wrong.

What Happens to Weight When You Stop

This is the question most women planning pregnancy are most anxious about, and it deserves an honest answer.

Weight regain after stopping GLP-1 medications is common and well-documented. The STEP 1 extension trial found that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year without continued medication. The metabolic improvements — reduced insulin resistance, lower androgen levels in PCOS, improved blood lipids — also partially reversed as weight returned.

This happens because GLP-1 medications work primarily through appetite suppression. When the medication stops, the pharmacological appetite suppression disappears. Unless alternative behavioural and nutritional habits have been established and maintained, the appetite that was being suppressed returns and eating patterns revert toward pre-treatment levels.

This is not inevitable — but it does require deliberate preparation during the washout period.

GLP-1, PCOS, and Fertility Planning

Women with PCOS face a specific set of considerations around GLP-1 medications and pregnancy planning that differ from the general population.

As covered in the GLP-1 and PCOS article, GLP-1 medications produce meaningful improvements in insulin resistance, androgen levels, and menstrual regularity in women with PCOS. These improvements may make the metabolic environment more favourable for conception and healthy pregnancy than the pre-treatment baseline.

The clinical approach many reproductive endocrinologists now use for PCOS patients who want to conceive: use GLP-1 medications to achieve metabolic improvement and weight loss, then transition off under medical supervision before attempting conception, aiming to carry the improved metabolic baseline into the conception attempt. The 2-month washout period is used for nutritional preparation and habit consolidation.

This is not a standard protocol and varies by clinician. Any fertility-related decisions involving GLP-1 medications should be made with a reproductive endocrinologist, not a GP alone.

GLP-1 Medications and Breastfeeding

GLP-1 medications are not recommended during breastfeeding. The FDA and manufacturers advise against use of semaglutide and tirzepatide while breastfeeding due to unknown effects on breast milk composition and potential effects on the infant.

There is very limited published data on the transfer of GLP-1 medications into breast milk. Semaglutide is a large peptide molecule and is unlikely to transfer in significant quantities — but “unlikely” is not the same as “established safe,” and the precautionary recommendation applies until better data exists.

Women who wish to resume GLP-1 medication after delivery should discuss timing with their healthcare provider in the context of their infant feeding plans.

Frequently Asked Questions

Research & References